South Korea
· Delayed Price · Currency is KRW S.Biomedics Statistics
Total Valuation
S.Biomedics has a market cap or net worth of KRW 254.88 billion. The enterprise value is 256.16 billion.
| Market Cap | 254.88B |
| Enterprise Value | 256.16B |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
S.Biomedics has 11.75 million shares outstanding. The number of shares has increased by 5.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 11.75M |
| Shares Change (YoY) | +5.22% |
| Shares Change (QoQ) | +2.22% |
| Owned by Insiders (%) | 22.10% |
| Owned by Institutions (%) | 0.46% |
| Float | 8.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.56 |
| PB Ratio | 13.92 |
| P/TBV Ratio | 22.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -38.29 |
| EV / Sales | 18.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -52.38 |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 1.03.
| Current Ratio | 2.49 |
| Quick Ratio | 2.20 |
| Debt / Equity | 1.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.84 |
| Interest Coverage | -6.84 |
Financial Efficiency
Return on equity (ROE) is -37.96% and return on invested capital (ROIC) is -11.07%.
| Return on Equity (ROE) | -37.96% |
| Return on Assets (ROA) | -8.89% |
| Return on Invested Capital (ROIC) | -11.07% |
| Return on Capital Employed (ROCE) | -16.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -52.43% |
| 50-Day Moving Average | 23,682.20 |
| 200-Day Moving Average | 26,968.70 |
| Relative Strength Index (RSI) | 45.61 |
| Average Volume (20 Days) | 169,530 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.Biomedics had revenue of KRW 13.73 billion and -6.69 billion in losses. Loss per share was -581.66.
| Revenue | 13.73B |
| Gross Profit | 6.71B |
| Operating Income | -5.44B |
| Pretax Income | -5.76B |
| Net Income | -6.69B |
| EBITDA | -3.72B |
| EBIT | -5.44B |
| Loss Per Share | -581.66 |
Balance Sheet
The company has 23.95 billion in cash and 18.78 billion in debt, giving a net cash position of 5.17 billion or 440.00 per share.
| Cash & Cash Equivalents | 23.95B |
| Total Debt | 18.78B |
| Net Cash | 5.17B |
| Net Cash Per Share | 440.00 |
| Equity (Book Value) | 18.31B |
| Book Value Per Share | 1,010.11 |
| Working Capital | 17.50B |
Cash Flow
In the last 12 months, operating cash flow was -3.50 billion and capital expenditures -1.39 billion, giving a free cash flow of -4.89 billion.
| Operating Cash Flow | -3.50B |
| Capital Expenditures | -1.39B |
| Free Cash Flow | -4.89B |
| FCF Per Share | -416.35 |
Margins
Gross margin is 48.84%, with operating and profit margins of -39.62% and -48.72%.
| Gross Margin | 48.84% |
| Operating Margin | -39.62% |
| Pretax Margin | -41.92% |
| Profit Margin | -48.72% |
| EBITDA Margin | -27.06% |
| EBIT Margin | -39.62% |
| FCF Margin | n/a |
Dividends & Yields
S.Biomedics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.22% |
| Shareholder Yield | -5.22% |
| Earnings Yield | -2.63% |
| FCF Yield | -1.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.Biomedics has an Altman Z-Score of 4.77.
| Altman Z-Score | 4.77 |
| Piotroski F-Score | n/a |